Cn5 - Cost-Effectiveness of Pembrolizumab Versus Standard-Of-Care Chemotherapies for First-Line Treatment of Pd-L1 Positive (≥50%) Metastatic Non-Small Cell Lung Cancer in France
Value in Health- United Kingdom
doi 10.1016/j.jval.2018.09.022
Full Text
Abstract
Available in
Date
October 1, 2018
Authors
Publisher
Elsevier BV